Novo Nordisk (NVO) said Thursday a phase 3a trial of oral semaglutide in children and adolescents aged between 10 and 17 years with type-2 diabetes showed a "superior reduction" in a measure of blood sugar control over placebo.
Results also showed a "well-tolerated" safety profile, consistent with prior semaglutide trials, the Danish drugmaker said.
Oral semaglutide is available as Rybelsus in the European Union and the US, and will be available in the US as Ozempic pill "soon," Novo Nordisk said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments